What is Bruceine A and where does it come from?

Bruceine A is a quassinoid—a highly oxygenated degraded triterpene—isolated from the seeds and fruits of Brucea javanica (L.) Merr., a tropical shrub used for centuries in traditional Chinese medicine. It belongs to a family of intensely bitter compounds responsible for many of the plant's bioactive properties, and is extracted using ethanol or methanol followed by chromatographic purification.

What does the research say about Bruceine A's anticancer activity?

Preclinical cell-based studies show that Bruceine A activates p38α MAPK signaling and inhibits PFKFB4 and GSK3β pathways in MIA PaCa-2 pancreatic cancer cells, disrupting metabolic reprogramming and survival signaling. All current evidence is from in vitro experiments; no animal tumor models or human clinical trials for Bruceine A in cancer have been published, so no conclusions about clinical efficacy can be drawn.

How potent is Bruceine A against Babesia parasites?

In canine erythrocyte culture assays, Bruceine A inhibited Babesia gibsoni growth at concentrations as low as 25 nM, achieving parasite elimination within 24 hours—a potency that exceeded the standard veterinary antibabesial drug diminazene aceturate under the same experimental conditions. These results are limited to in vitro models; no in vivo animal or human antibabesial trials have been conducted with Bruceine A.

Is Bruceine A safe to take as a supplement?

Bruceine A is not approved or available as a dietary supplement, and no human safety data, toxicology studies, or established safe dose ranges exist for this compound. Its extreme nanomolar-range biological potency raises significant concern for off-target toxicity, and the quassinoid chemical class is associated with gastrointestinal irritation, potential hepatotoxicity, and cytotoxic effects; use outside controlled laboratory or clinical research settings is not supported.

How does Bruceine A differ from other Brucea javanica quassinoids like brusatol or bruceine D?

While all are quassinoids from Brucea javanica sharing a degraded triterpene scaffold, they differ in oxygenation pattern, stereochemistry, and demonstrated biological targets: brusatol is widely studied as an NRF2 inhibitor that sensitizes cancer cells to chemotherapy, while bruceine D induces apoptosis in NSCLC cells via ROS/JNK/Bcl-2 pathways (IC50 0.5–17.89 µM) and shows antidiabetic effects in rat models. Bruceine A is most notable for exceptional antibabesial potency at 25 nM and pancreatic cancer cell signaling modulation via p38α MAPK/PFKFB4/GSK3β, distinguishing it mechanistically from its close structural relatives.

What is the bioavailability of Bruceine A, and does it absorb better in certain forms?

Bruceine A is a lipophilic quassinoid that shows improved absorption when delivered with fat or oil carriers, as demonstrated in traditional preparations of Brucea javanica. Most clinical research has utilized standardized extracts containing 10–40% quassinoids, though specific bioavailability data for isolated Bruceine A in humans remains limited. The compound's rapid in vitro activity against Babesia parasites suggests reasonable cellular uptake, but individual absorption may vary based on gut health and formulation.

Is Bruceine A safe to use alongside antimalarial or antiparasitic medications?

Bruceine A should be used cautiously with prescription antimalarials or antiparasitic drugs, as both act on similar parasite pathways and concurrent use could increase toxicity risk or create unpredictable interactions. No formal drug interaction studies have been conducted for Bruceine A with common antiparasitic agents like artemisinin derivatives or diminazene aceturate. Consultation with a healthcare provider before combining Bruceine A with any prescription antiparasitic treatment is strongly recommended.

Who would benefit most from Bruceine A supplementation—what populations show the greatest need?

Bruceine A may be most relevant for individuals in regions where Babesia or certain parasitic infections are endemic, particularly those seeking natural adjunctive support for parasitic conditions, though clinical evidence in human populations remains preliminary. People with compromised immune function or chronic parasitic infections could theoretically benefit from its potent in vitro antibabesial activity, but controlled human trials have not yet established safety or efficacy in these groups. Individuals in developed countries without documented parasitic infection currently lack a clear clinical basis for supplementation.

Bruceine A

Bruceine A is a quassinoid compound extracted from Brucea javanica that exerts antiparasitic and anticancer effects by activating p38α MAPK signaling, inhibiting PFKFB4/GSK3β pathways, and directly suppressing intraerythrocytic parasite growth. In preclinical antibabesial assays, Bruceine A inhibited Babesia gibsoni proliferation in canine erythrocytes at concentrations as low as 25 nM, eliminating parasites within 24 hours and outperforming the standard veterinary drug diminazene aceturate.

Category: Compound Evidence: 1/10 Tier: Preliminary

Origin & History

Bruceine A is a quassinoid secondary metabolite isolated primarily from the seeds and fruits of Brucea javanica (L.) Merr., a shrub native to tropical and subtropical regions of Southeast Asia, northern Australia, and southern China. The plant thrives in disturbed forest margins, roadsides, and secondary growth habitats at low to mid elevations, and has been cultivated in China for centuries as a traditional medicinal herb. Commercial extraction of Bruceine A relies on ethanol or methanol extraction of dried seeds and fruits, followed by activity-guided chromatographic fractionation to isolate this specific quassinoid constituent.

Historical & Cultural Context

Brucea javanica, the source plant of Bruceine A, has been documented in traditional Chinese medicine (TCM) for over a millennium under the name 'Ya Dan Zi' (鸦胆子), meaning 'crow's gallbladder seed,' reflecting its extreme bitterness characteristic of quassinoid-rich plant material. The seeds were traditionally prescribed for intermittent fevers consistent with malaria, amoebic and bacillary dysentery, and as a topical treatment for warts and corns, with oral administration typically involving small numbers of seeds encased in gelatin capsules or soft bread to reduce gastrointestinal irritation from the intensely bitter and emetic constituents. In Southeast Asian ethnobotany, the plant was similarly employed for malaria and tropical parasitic infections, and its seeds were incorporated into folk remedies across Indonesia, Malaysia, and the Philippines. The isolation and structural characterization of individual quassinoids including Bruceine A emerged from modern phytochemical investigation of this TCM plant beginning in the latter half of the 20th century, linking the traditional antimalarial and antidysenteric uses to specific bitter terpenoid compounds.

Health Benefits

- **Antibabesial Activity**: Bruceine A inhibits Babesia gibsoni growth in canine erythrocytes at nanomolar concentrations (as low as 25 nM), with parasite clearance observed within 24 hours, surpassing the potency of the reference antibabesial drug diminazene aceturate in vitro.
- **Anticancer Potential (Pancreatic Cancer)**: In MIA PaCa-2 pancreatic cancer cells, Bruceine A activates p38α MAPK signaling and suppresses PFKFB4 and GSK3β pathways, disrupting glycolytic flux and survival signaling critical for pancreatic ductal adenocarcinoma progression.
- **Antimalarial Properties**: As a member of the quassinoid class from Brucea javanica, Bruceine A contributes to the plant's traditional and preclinical antimalarial activity, with quassinoids broadly recognized for inhibiting intraerythrocytic Plasmodium replication, though species-specific molecular targets for Bruceine A remain under investigation.
- **Insecticidal and Antifeedant Effects**: Related bruceines from the same plant demonstrate potent insecticidal and antifeedant properties, and Bruceine A shares structural features associated with non-specific inhibition of invertebrate growth pathways, relevant to agricultural biocontrol research.
- **Apoptosis Induction (Class Effect)**: Closely related quassinoids from B. javanica, including bruceine D, induce apoptosis in non-small cell lung cancer cells via ROS elevation, pJNK upregulation, Bcl-2 downregulation, and BAX/caspase-3/PARP activation, with IC50 values of 0.5–2.7 µM at 48 hours, suggesting Bruceine A may share convergent proapoptotic mechanisms.
- **Anti-inflammatory Context**: Traditional use of Brucea javanica for dysentery and tropical infections implies quassinoid-mediated anti-inflammatory activity; Bruceine A's modulation of MAPK cascades is consistent with suppression of proinflammatory cytokine signaling, though direct anti-inflammatory data specific to Bruceine A are not yet published.
- **Antidiabetic Class Association**: Structurally related quassinoids bruceines D and E reduced fasting blood glucose by 73.57 ± 13.64% and 87.99 ± 2.91%, respectively, in streptozotocin-induced diabetic rat models, placing Bruceine A within a chemotype of potential metabolic interest, pending direct investigation.

How It Works

Bruceine A activates p38α mitogen-activated protein kinase (MAPK) signaling in pancreatic cancer cells, a stress-responsive pathway that can trigger cell cycle arrest and apoptosis when sustained, while simultaneously inhibiting PFKFB4 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoform 4), a hypoxia-inducible glycolytic regulator that cancer cells depend on for metabolic reprogramming, and suppressing GSK3β, a serine/threonine kinase involved in cell survival and proliferation. In intraerythrocytic parasitic contexts, Bruceine A directly inhibits Babesia gibsoni replication at nanomolar concentrations, though the precise parasite-specific molecular target—whether membrane integrity, mitochondrial function, or metabolic enzyme inhibition—has not been fully characterized. The broader quassinoid scaffold to which Bruceine A belongs is recognized for intercalating into or disrupting ribosomal function and electron transport chain activity in eukaryotic parasites, mechanisms consistent with its high-potency, rapid-acting antiparasitic profile. Structural analogy with bruceine D further suggests potential engagement of JNK/PI3K/AKT signaling axes and autophagic pathways (evidenced by LC3-II accumulation in lung cancer models), though these targets require direct experimental confirmation for Bruceine A itself.

Scientific Research

The evidence base for Bruceine A consists exclusively of in vitro cell-based assays and limited in vivo animal experiments, with no registered or completed human clinical trials identified as of the current literature review. Key preclinical findings include potent antibabesial activity at 25 nM against Babesia gibsoni in canine erythrocyte cultures and mechanistic studies in MIA PaCa-2 pancreatic cancer cell lines demonstrating p38α MAPK activation and PFKFB4/GSK3β inhibition; sample sizes, replication numbers, and full statistical reporting vary across published studies. Comparative data for related quassinoids (bruceine D IC50 0.5–17.89 µM in NSCLC lines; bruceines D/E glucose reduction of 73–88% in STZ-rat models) provide contextual chemotype relevance but cannot be directly extrapolated to Bruceine A's efficacy or safety profile. Overall, the evidence is preliminary and preclinical in nature, lacking pharmacokinetic, toxicokinetic, dose-escalation, or any Phase I–III human data, rendering translation to clinical application speculative at this stage.

Clinical Summary

No clinical trials investigating Bruceine A in human subjects have been identified in available databases or published literature, meaning all efficacy and safety inferences derive entirely from cell culture and animal model experiments. Preclinical antibabesial studies using canine erythrocyte cultures represent the most quantitatively robust data point, demonstrating parasite inhibition at 25 nM—a concentration well below cytotoxic thresholds established for related quassinoids—but the translational relevance to human Babesia or Plasmodium infections remains undemonstrated. Pancreatic cancer mechanistic studies in MIA PaCa-2 cells provide molecular target identification (p38α MAPK, PFKFB4, GSK3β) but lack tumor regression endpoints, survival data, or in vivo xenograft confirmation specific to Bruceine A. Confidence in any clinical application is very low; Bruceine A must be considered a research-phase molecule without established therapeutic indication, dosing regimen, or human safety profile.

Nutritional Profile

Bruceine A is a pure isolated quassinoid compound (a highly oxygenated, degraded triterpene with molecular formula C20H24O9, molecular weight 412.39 g/mol) and does not constitute a nutritional ingredient in the conventional macronutrient or micronutrient sense; it contributes no calories, protein, fat, carbohydrate, vitamins, or minerals. As a secondary plant metabolite, it is present in trace-to-minor quantities within Brucea javanica seed material alongside other quassinoids (bruceines C–H, brusatol, bruceosides), though precise weight-per-weight concentrations in raw plant material have not been standardized in published literature. Bioavailability factors including oral absorption, aqueous solubility, cytochrome P450 metabolism, and blood-brain barrier penetration are entirely unstudied for Bruceine A specifically; the quassinoid class generally exhibits moderate lipophilicity consistent with passive membrane permeation. No dietary reference intakes, tolerable upper limits, or nutritional adequacy considerations apply to this compound.

Preparation & Dosage

- **Laboratory Extraction (Research Use Only)**: Isolated via ethanol or methanol extraction of dried Brucea javanica seeds/fruits, followed by silica gel or reverse-phase HPLC chromatography; no standardized commercial extract exists.
- **In Vitro Antibabesial Concentration**: 25 nM used in canine erythrocyte assays to achieve parasite elimination within 24 hours; this is a cell-culture concentration, not a human dose.
- **In Vitro Anticancer Concentration**: Micromolar range (exact IC50 for Bruceine A in pancreatic cancer cells not fully published); structurally related bruceine D active at 0.5–2.7 µM (48 h) in NSCLC lines.
- **Traditional Crude Preparation**: Brucea javanica fruits/seeds administered as decoctions or fixed oils orally in traditional Chinese medicine, but Bruceine A content in such preparations is unstandardized and unquantified.
- **No Established Human Dose**: There is no scientifically validated or regulatory-approved dosing regimen for Bruceine A as a supplement or pharmaceutical; extrapolation from preclinical data to human dosing is not supported by current evidence.
- **Timing/Administration Notes**: Preclinical experiments involve direct cell-culture application; oral bioavailability, first-pass metabolism, protein binding, and tissue distribution in humans are entirely uncharacterized.

Synergy & Pairings

No experimentally validated synergistic combinations involving Bruceine A have been published; however, within the quassinoid research context, combinations of Brucea javanica extracts with artemisinin-based antimalarials have been explored conceptually given complementary mechanisms of intraerythrocytic parasite disruption, potentially offering additive or synergistic antiparasitic effects through distinct molecular targets. In anticancer research, co-administration of p38α MAPK activators with conventional chemotherapeutics such as gemcitabine (standard of care in pancreatic cancer) represents a rational mechanistic hypothesis, as p38α activation can sensitize cancer cells to DNA-damaging agents by impairing pro-survival signaling, though no Bruceine A-specific combination data exist. Any synergy claims for Bruceine A remain entirely speculative and require dedicated in vitro and in vivo combination index studies before scientific or clinical conclusions can be drawn.

Safety & Interactions

No human safety data, toxicology studies, maximum tolerated dose evaluations, or pharmacovigilance reports specific to isolated Bruceine A exist in the published literature, making definitive safety characterization impossible. The extreme potency of Bruceine A at nanomolar concentrations in biological assays raises significant concern for off-target cytotoxicity at doses required for systemic therapeutic effect; related quassinoids from Brucea javanica are associated with gastrointestinal toxicity (nausea, vomiting, diarrhea), potential hepatotoxicity, and non-specific growth inhibitory effects observed in insecticidal models. No drug interaction data are available, though MAPK and GSK3β pathway modulation theoretically risks pharmacodynamic interactions with oncology agents, immunosuppressants, and antidiabetic drugs metabolized through overlapping signaling cascades; cytochrome P450 interaction potential is uncharacterized. Bruceine A is strictly contraindicated in pregnancy and lactation based on complete absence of safety data and the recognized uterotonic and cytotoxic properties of the quassinoid chemical class; use outside controlled research settings is not supported by any regulatory body.